TY - JOUR
T1 - Impact of a single fecal microbiome transplantation in adult women with anorexia nervosa
T2 - an open-label feasibility pilot trial
AU - Panah, Farhad M
AU - Støving, René Klinkby
AU - Sjögren, Magnus
AU - Micali, Nadia
AU - Maschek, Sina
AU - Reis, Kia Daniela
AU - Mirsepasi-Lauridsen, Hengameh Chloé
AU - Petersen, Andreas Munk
AU - Nielsen, Dennis Sandris
AU - Helms, Morten
AU - Rasmussen, Morten Arendt
AU - Barfod, Kenneth Klingenberg
N1 - © 2026. The Author(s).
PY - 2026/1/14
Y1 - 2026/1/14
N2 - Anorexia nervosa (AN) is a severe mental disorder characterized by restrictive eating and disturbance in the way one's body weight or shape is experienced, often accompanied by depression and anxiety. Current evidence-based treatments for AN have limited efficacy, with less than half of the patients achieving full recovery in long-term follow-up studies. Recent findings have identified gut microbiota (GM) dysbiosis as a potential contributor to AN pathology through the gut-brain axis. This open-label, non-randomized, feasibility trial (Clinicaltrials.gov Identifier: NCT05834010) evaluated the feasibility of utilizing fecal microbiota transplantation (FMT) to modify the GM and GM-associated signaling in females with AN and to examine biological effects following a single FMT procedure. Adult female participants diagnosed with AN were recruited. FMT was administered either orally via capsules or as rectal enema. Stool and blood samples were collected pre- and one week post-FMT to assess GM composition, hormonal changes, and biomarkers. Primary endpoints: Feasibility of FMT in individuals with AN and preferred route of FMT. Secondary endpoints: A single FMT treatment can alter GM composition in individuals with AN short term and relevant gut brain signaling in serum. 18/22 participants (81%) completed FMT and sampling and 19/22 participants chose oral capsules, with no serious adverse effects reported. GM analysis showed significant shifts toward donor composition 1-week post-FMT, with improved stool consistency. No significant changes were observed in psychopathology measures or appetite-related biomarkers. Oral FMT is a feasible intervention for adult women with AN, leading to changes in GM profile. Future studies should focus on placebo-controlled trials to assess the efficacy of repeated oral treatments and explore long-term effects on GM, appetite, body weight, sex hormones, disorder-specific symptoms, and overall well-being.
AB - Anorexia nervosa (AN) is a severe mental disorder characterized by restrictive eating and disturbance in the way one's body weight or shape is experienced, often accompanied by depression and anxiety. Current evidence-based treatments for AN have limited efficacy, with less than half of the patients achieving full recovery in long-term follow-up studies. Recent findings have identified gut microbiota (GM) dysbiosis as a potential contributor to AN pathology through the gut-brain axis. This open-label, non-randomized, feasibility trial (Clinicaltrials.gov Identifier: NCT05834010) evaluated the feasibility of utilizing fecal microbiota transplantation (FMT) to modify the GM and GM-associated signaling in females with AN and to examine biological effects following a single FMT procedure. Adult female participants diagnosed with AN were recruited. FMT was administered either orally via capsules or as rectal enema. Stool and blood samples were collected pre- and one week post-FMT to assess GM composition, hormonal changes, and biomarkers. Primary endpoints: Feasibility of FMT in individuals with AN and preferred route of FMT. Secondary endpoints: A single FMT treatment can alter GM composition in individuals with AN short term and relevant gut brain signaling in serum. 18/22 participants (81%) completed FMT and sampling and 19/22 participants chose oral capsules, with no serious adverse effects reported. GM analysis showed significant shifts toward donor composition 1-week post-FMT, with improved stool consistency. No significant changes were observed in psychopathology measures or appetite-related biomarkers. Oral FMT is a feasible intervention for adult women with AN, leading to changes in GM profile. Future studies should focus on placebo-controlled trials to assess the efficacy of repeated oral treatments and explore long-term effects on GM, appetite, body weight, sex hormones, disorder-specific symptoms, and overall well-being.
KW - Humans
KW - Female
KW - Anorexia Nervosa/therapy
KW - Fecal Microbiota Transplantation/methods
KW - Adult
KW - Pilot Projects
KW - Feasibility Studies
KW - Gastrointestinal Microbiome/physiology
KW - Young Adult
KW - Feces/microbiology
KW - Treatment Outcome
KW - Dysbiosis/therapy
KW - Adolescent
U2 - 10.1038/s41467-026-68455-8
DO - 10.1038/s41467-026-68455-8
M3 - Journal article
C2 - 41535289
SN - 2041-1722
VL - 17
SP - 1747
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1747
ER -